Show
Sort by
-
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE) : an open-label extension study
-
Safety of reslizumab in uncontrolled asthma with eosinophilia : a pooled analysis from 6 trials
-
Dupilumab reduces severe outpatient asthma exacerbations, cumulative dose, and total number of days of systemic corticosteroid use among patients with moderate-to-severe type-2 asthma
-
Effect of Dupilumab on patient-reported breathing and rescue medication use
-
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials
-
- Journal Article
- A1
- open access
Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma
-
- Journal Article
- A1
- open access
Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis
-
Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year
-
- Journal Article
- A1
- open access
Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history
-
Dupilumab demonstrates rapid and sustained improvements in daily asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma : data from the Liberty Asthma Quest study